What is the best month for Eli Lilly?
Since 1972, November has been the strongest month for Eli Lilly, averaging +3.09% and rising in 70% of 54 years. September has been the weakest, at -0.49%.
We rate the November pattern as strong and the September pattern as no clear pattern. December comes second at +2.59%. A strong month is when prices have tended to rise, not a promise that they will.
Every month, ranked
Eli Lilly, 1972 to 2026
| Rank | Month | Average | Median | Up years | Pattern |
|---|---|---|---|---|---|
| 1 | November | +3.09% | +2.98% | 70% | strong |
| 2 | December | +2.59% | +1.05% | 56% | moderate |
| 3 | June | +2.45% | +3.11% | 65% | strong |
| 4 | May | +2.21% | +0.64% | 59% | moderate |
| 5 | October | +2.11% | +2.28% | 60% | weak |
| 6 | April | +1.74% | +1.06% | 58% | weak |
| 7 | March | +1.05% | +1.31% | 61% | weak |
| 8 | February | +0.84% | +0.74% | 54% | no clear pattern |
| 9 | January | +0.77% | -0.36% | 50% | no clear pattern |
| 10 | August | +0.70% | -0.02% | 49% | no clear pattern |
| 11 | July | -0.24% | +0.58% | 54% | no clear pattern |
| 12 | September | -0.49% | -0.73% | 45% | no clear pattern |
Exact date ranges
Seasonal windows that held in at least 75% of years
Likely range of the hit rate 59% to 88%. 1996 to 2010: 60%, 2011 to 2025: 93%.
Likely range of the hit rate 59% to 88%. 1996 to 2010: 73%, 2011 to 2025: 80%.
Likely range of the hit rate 74% to 97%. 1996 to 2010: 87%, 2011 to 2025: 93%.
Why it might happen
- Obesity and diabetes drug sales, manufacturing capacity and pricing policy.
- Clinical trial readouts and US drug-pricing headlines.
Full statistics, technicals and event reactions: Eli Lilly. How to read these numbers: guide.
Alerts for Eli Lilly
Pick your markets. We email when something relevant moves. Free during launch.
Not investment advice. Market Seasonality publishes historical statistics, news summaries and scenario analysis for information and education. Past patterns do not guarantee future results. Nothing here is a recommendation to buy, sell or hold any asset, and scenarios describe possible paths without predicting them. See the disclaimer and methodology.